Investors aiming to benefit from the next group of market leaders frequently use a two-part method, merging the prospective view of fundamental analysis with the timing cues of technical analysis. One specific tactic looks for solid growth stocks that are also showing encouraging technical breakout formations. The idea is simple: find firms with solid and speeding up business basics, like earnings growth, profitability, and financial condition, that are at the same time having their stock prices trade in a narrow range that frequently comes before a major upward price change. This combination indicates a stock is not only fundamentally healthy but might also be about to receive wider market attention and price movement.
Neurocrine Biosciences Inc (NASDAQ:NBIX) offers an interesting example for this investment framework. As a biopharmaceutical company concentrated on neuroscience with a group of sold products and a hopeful development pipeline, its business story is one of expansion. An examination of its fundamental and technical condition shows why it recently appeared on such a search filter.
Fundamental Strength: The Engine for Growth
The center of any growth investment idea exists in the company's financial results and future view. Neurocrine's fundamental picture, as described in its ChartMill Fundamental Analysis Report, displays several points of significant strength that match the requirements for a solid growth stock.
-
Notable Growth Measures: The company receives a high Growth Rating of 9 out of 10. This is fueled by strong past performance, including a 41.64% increase in Earnings Per Share (EPS) over the last year and a five-year average yearly Revenue increase of 22.29%. Importantly, this speed is forecasted to persist, with analysts predicting future EPS growth of almost 27% each year.
-
Firm Profitability and Financial Condition: Growth is most lasting when backed by profitability and a solid balance sheet. Neurocrine gets a 7 for both Profitability and Financial Health.
- Its Return on Equity (14.71%) and Return on Invested Capital (11.30%) place in the top group of its biotechnology industry competitors.
- The company has no debt, giving notable financial adaptability and strength. Paired with a high Altman-Z score and solid liquidity measures, this describes a financially sound business.
-
Fair Valuation in Perspective: While its standard P/E ratio seems high at 27.56, about equal to the S&P 500, its valuation looks more appealing when seen through growth-related measures. Its Price/Forward Earnings ratio of 20.74 and Enterprise Value/EBITDA ratio are lower than most of its industry competitors. For a growth investor, paying a fair price for a company showing this mix of high growth, high profitability, and excellent financial condition is a main factor.
Technical Setup: The Chart Indicates a Possible Catalyst
A solid fundamental story can stay unnoticed by the market for a period. Technical analysis assists in spotting when a stock's price movement might be matching its basic business strength. Per Neurocrine's ChartMill Technical Analysis Report, the stock is now showing what is called a consolidation or "setup" formation, getting a Setup Rating of 8 out of 10.
The stock's long-term direction has been down, but the short-term direction has lately become neutral. The price has been changing within a fairly small band between about $125 and $134 over the last month, which has lowered instability. This kind of price tightening often happens before a clear move. The technical report notes a defined resistance area just above the present price, beginning near $130.14. For chart analysts, a maintained move above this specific resistance level on good volume could indicate the start of a new rising direction, possibly giving a planned entry point that matches the timing of the investment with a change in market movement.
Why This Combination Is Important
This blended method reduces main dangers. Investing based only on a technical formation is similar to following movement without knowing the cause; the change could be short. On the other hand, buying a fundamentally solid stock that is in a continuous decline can strain an investor's patience and funds as they wait for a mood change. By needing both situations, the tactic looks for companies where the fundamental "engine" is strong and the technical "indicator" is showing a sign that the stock may be getting ready to move. In Neurocrine's situation, its fast earnings growth, debt-free balance sheet, and industry-top margins supply the engine. The present price consolidation close to an important resistance level supplies the possible starting point.
Looking for More Chances
Neurocrine Biosciences shows the kind of chance a mixed fundamental and technical filter can find. For investors wanting to use this framework to locate other possible choices, the set "Strong Growth Stock Technical Setups" filter is ready to examine and adjust.
Disclaimer: This article is for information only and does not form investment guidance, a suggestion, or a bid or request to buy or sell any securities. The study shown is based on information and reports supplied by ChartMill and should not be the only ground for any investment choice. Investing in stocks includes risk, including the possible loss of original investment. Always do your own complete investigation and think about talking with a registered financial consultant before making any investment choices.